Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of 2B3-201 in healthy volunteers and patients with multiple sclerosis
NL-OMON40606Phase 1Active, not recruiting
- Sponsor
- 2-BBB Therapeutics
- Start
- Nov 2013
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ENX-201 in multiple sclerosis (MS) (3 arms), sponsored by 2-BBB Therapeutics. Primary endpoints: Adverse events, Concomitant medications and 11 more. Started Nov 2013; status: active, not recruiting.
02
Drugs
ENX-201
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON40606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40606.